Invention Application
US20060089375A1 Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
审中-公开
吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途
![Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors](/docs/US/2006-04-27/US20060089375A1/abs.jpg.600x600.jpg)
- Patent Title: Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
- Patent Title (中): 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途
-
Application No.: US10527866Application Date: 2003-09-12
-
Publication No.: US20060089375A1Publication Date: 2006-04-27
- Inventor: David Allen , Diane Coe , Caroline Cook , Michael Dowle , Christophen Edlin , Julie Hamblin , Martin Johnson , Paul Jones , Richard Knowles , Mika Lindvall , Charlotte Mitchell , Alison Redgrave , Peter Ward
- Applicant: David Allen , Diane Coe , Caroline Cook , Michael Dowle , Christophen Edlin , Julie Hamblin , Martin Johnson , Paul Jones , Richard Knowles , Mika Lindvall , Charlotte Mitchell , Alison Redgrave , Peter Ward
- Priority: GB0221455.9 20020916; GB0230045.7 20021223; GB0306595.0 20030321; GB0308017.3 20030407; GB0319708.4 20030821; GB0321074.7 20030909
- International Application: PCT/EP03/11814 WO 20030912
- Main IPC: C07D471/02
- IPC: C07D471/02 ; A61K31/4745
![Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors](/abs-image/US/2006/04/27/US20060089375A1/abs.jpg.150x150.jpg)
Abstract:
The invention relates to a compound of formula (I) or a salt thereof: wherein: R1 is C1-4alkyl, C1-3fluoroalkyl, —CH2CH2OH or —CH2CH2CO2C1-2alkyl; R2 is a hydrogen atom (H), methyl or C1fluoroalkyl; R3 is optionally substituted C3-8cycloalkyl or optionally substituted mono-unsaturated-C5-7cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n1 and n2 independently are 1 or 2; and in which Y is O, S, SO2, or NR10; or R3 is a bicyclic group (dd) or (ee): and wherein X is NR4R5 or OR5a. The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.
Information query
